Blood Proteins Reveal Which Aging Cells May Raise Disease Risk, Landmark Study Shows
Key Insights
A large plasma proteomics study across 60,000+ individuals shows that cell-type-specific aging signatures in blood can predict future disease risk and mortality over 15 years.
Extreme astrocyte aging tripled Alzheimer's disease (search) risk in APOE4 (search) homozygotes, while youthful astrocytes reduced risk by over 60%, independent of genetic predisposition.
Individuals with extreme skeletal myocyte aging were 12.7 times more likely to develop ALS, and concurrent respiratory cell aging raised lung cancer (search) risk 58% beyond smoking alone.
A landmark study published in Nature Medicine demonstrates that aging patterns in specific cell types—detectable through routine blood protein analysis—can predict who is more vulnerable to age-related diseases and who may remain resilient. Analyzing over 7,000 plasma proteins in more than 60,000 individuals across multiple international cohorts, researchers developed cellular aging clocks that estimate the biological age of over 40 cell types spanning the nervous, immune, endocrine, and musculoskeletal systems.
The findings suggest that plasma proteomic signatures could one day enable clinicians to stratify risk and explore more personalized approaches to prevention and treatment, potentially identifying at-risk individuals years before disease onset.
Astrocyte Aging and Alzheimer's Disease (search) Risk
Among the most striking findings, extreme astrocyte aging emerged as a powerful predictor of incident Alzheimer's disease (search) (AD). Individuals with extreme astrocyte aging demonstrated a 12.59-fold increased risk of incident AD compared to those with youthful aging. Kaplan–Meier analyses revealed significant risk stratification by aging status (log-rank P < 0.0001), which remained robust across APOE genotype subgroups.
The study revealed pronounced synergistic effects between APOE genotype and astrocyte aging. Individuals homozygous for APOE4 (search) with extreme astrocyte aging showed the highest cumulative incidence of 38.3% over 15 years of follow-up, compared to 12.6% for homozygotes with normal astrocyte aging. APOE3/4 carriers with extreme astrocyte aging showed 10.2% cumulative incidence versus 2.7% with normal astrocyte aging.
Of potential therapeutic relevance, none of the 23 APOE4 (search)/4 carriers with youthful astrocytes and only 1.8% of APOE3/4 carriers with youthful astrocytes developed AD. "Youthful astrocytes reduced AD risk by over 60%," the authors noted, suggesting that maintaining youthful astrocyte function may represent a therapeutic strategy to mitigate disease burden, especially in genetically predisposed individuals.
Excess AD risk associated with extreme astrocyte aging (HR = 5.16, 95% CI 4.06–6.56) was comparable to APOE4 (search) carrier status (HR = 5.30, 95% CI 4.54–6.18), exceeding both polygenic risk score (HR = 2.14, 95% CI 1.92–2.39) and older chronological age (HR = 1.24, 95% CI 1.22–1.27). Women carrying both APOE4 and astrocyte extreme aging faced the highest risk (HR = 14.23, 95% CI 9.86–20.54).
Skeletal Muscle Aging Predicts ALS
The strongest association among all disease-cell type pairs was between amyotrophic lateral sclerosis (search) (ALS) and skeletal myocyte aging (r = 0.43, adjusted P = 1.36 × 10⁻¹⁵). Individuals with extreme skeletal myocyte aging exhibited a substantially increased risk of incident ALS compared to those with youthful aging (HR = 12.74). In the GNPC cohort, 53 of 57 (93.0%) skeletal myocyte extreme agers had an ALS diagnosis.
Cardiomyocytes also showed accelerated aging in ALS patients (r = 0.33, adjusted P = 4.08 × 10⁻⁹), consistent with emerging evidence of cardiac abnormalities in ALS. The relationship between accelerated skeletal muscle aging and future ALS diagnosis persisted even when considering only cases diagnosed more than three years after blood draw, suggesting pathological mechanisms affecting muscle tissue may begin years before symptom onset.
Cancer and Chronic Disease Prediction
For lung cancer (search), concurrent extreme aging in alveolar type 2 cells and the broader respiratory epithelial lineage was most prognostic (HR = 8.39, 95% CI 6.68–10.52; HR = 8.47, 95% CI 6.69–10.71, respectively). Current smokers with extreme aging in both cell types exhibited the highest risk (HR = 15.33, 95% CI 11.02–21.31), yielding 58% higher hazard than current smoking alone (HR = 9.69, 95% CI 8.04–11.68).
For type 2 diabetes (search), myeloid lineage extreme aging demonstrated the strongest prognostic value (HR = 3.88, 95% CI 3.33–4.52). For chronic obstructive pulmonary disease (search), concurrent extreme aging in alveolar type 2 cells and respiratory epithelial lineage showed the most prognostic power (HR = 6.31 and HR = 5.45, respectively). For heart failure (search), extreme aging in muscle cells and fibroblasts was most prognostic (HR = 4.65 and HR = 4.62, respectively).
Mortality and the Polycellular Aging Risk Score
Cellular aging signatures strongly predicted all-cause mortality. The strongest associations were observed for extreme aging in muscle lineage cells (HR = 4.38, 95% CI 4.00–4.80) and skeletal myocytes (HR = 4.18, 95% CI 3.82–4.57). A striking dose-response relationship emerged: individuals with normal aging profiles maintained approximately 90% survival over 15 years, whereas those with over 20 extremely aged cell types showed approximately 34% survival.
The researchers developed a polycellular aging risk score (PARS) encompassing a composite of cell types. Kaplan–Meier analyses showed clear risk stratification in both training and test sets (log-rank P < 0.0001), with reduced survival among high-risk individuals. This finding was reproduced in an independent validation cohort despite differences in proteomics assay technology.
Study Design and Limitations
The researchers used two separate plasma protein profiling platforms—SomaScan (7,289 proteins) and Olink (search) (2,923 proteins)—and evaluated models across three large population cohorts: the Global Neurodegeneration Proteomics Consortium (GNPC, 14,281 participants), the 1946 National Survey of Health and Development (NSHD, 1,803 participants), and the UK Biobank (search) (UKB, 44,458 participants).
The authors noted that the findings require validation in broader populations, as the models relied on Human Protein Atlas cell-type annotations, plasma proteins may not always directly reflect cellular gene activity, and the study cohorts were predominantly older and Caucasian.
Modifiable Risk Factors and Genetic Influences
The study found that cellular age gaps demonstrated associations with modifiable risk factors. Individuals with concurrent smoking and obesity showed widespread increases in biological age across multiple cell types, while those with a healthy lifestyle—defined as never smoking, no alcohol consumption, BMI lower than 25, sufficient sleep, and regular exercise—showed overall younger cellular ages.
APOE genotype showed dose-dependent, antagonistic effects: APOE2 carriers exhibited significantly younger astrocyte profiles but older macrophages, while APOE4 (search) carriers showed the inverse, suggesting antagonistic pleiotropy operating at cellular resolution.
The findings, if confirmed across broader, more diverse populations, could eventually enable clinicians to incorporate protein profiling tests into disease risk stratification and targeted monitoring strategies, potentially improving the standard of care for age-related conditions.